Next generation risk assessment for skin sensitisation: A case study with propyl paraben

2021 ◽  
Vol 123 ◽  
pp. 104936
Author(s):  
Hind Assaf Vandecasteele ◽  
Françoise Gautier ◽  
Fleur Tourneix ◽  
Erwin van Vliet ◽  
Dagmar Bury ◽  
...  
2020 ◽  
Vol 117 ◽  
pp. 104755
Author(s):  
Françoise Gautier ◽  
Fleur Tourneix ◽  
Hind Assaf Vandecasteele ◽  
Erwin van Vliet ◽  
Dagmar Bury ◽  
...  

2020 ◽  
Vol 176 (1) ◽  
pp. 236-252 ◽  
Author(s):  
Maria T Baltazar ◽  
Sophie Cable ◽  
Paul L Carmichael ◽  
Richard Cubberley ◽  
Tom Cull ◽  
...  

Abstract Next-Generation Risk Assessment is defined as an exposure-led, hypothesis-driven risk assessment approach that integrates new approach methodologies (NAMs) to assure safety without the use of animal testing. These principles were applied to a hypothetical safety assessment of 0.1% coumarin in face cream and body lotion. For the purpose of evaluating the use of NAMs, existing animal and human data on coumarin were excluded. Internal concentrations (plasma Cmax) were estimated using a physiologically based kinetic model for dermally applied coumarin. Systemic toxicity was assessed using a battery of in vitro NAMs to identify points of departure (PoDs) for a variety of biological effects such as receptor-mediated and immunomodulatory effects (Eurofins SafetyScreen44 and BioMap Diversity 8 Panel, respectively), and general bioactivity (ToxCast data, an in vitro cell stress panel and high-throughput transcriptomics). In addition, in silico alerts for genotoxicity were followed up with the ToxTracker tool. The PoDs from the in vitro assays were plotted against the calculated in vivo exposure to calculate a margin of safety with associated uncertainty. The predicted Cmax values for face cream and body lotion were lower than all PoDs with margin of safety higher than 100. Furthermore, coumarin was not genotoxic, did not bind to any of the 44 receptors tested and did not show any immunomodulatory effects at consumer-relevant exposures. In conclusion, this case study demonstrated the value of integrating exposure science, computational modeling and in vitro bioactivity data, to reach a safety decision without animal data.


Author(s):  
G. Reynolds ◽  
J. Reynolds ◽  
N. Gilmour ◽  
R. Cubberley ◽  
S. Spriggs ◽  
...  

2020 ◽  
Vol 116 ◽  
pp. 104721 ◽  
Author(s):  
Nicola Gilmour ◽  
Petra S. Kern ◽  
Nathalie Alépée ◽  
Fanny Boislève ◽  
Dagmar Bury ◽  
...  

2008 ◽  
Vol 36 (5) ◽  
pp. 557-568 ◽  
Author(s):  
Gavin Maxwell ◽  
Maja Aleksic ◽  
Aynur Aptula ◽  
Paul Carmichael ◽  
Julia Fentem ◽  
...  

Allergic Contact Dermatitis (ACD; chemical-induced skin sensitisation) represents a key consumer safety endpoint for the cosmetics industry. At present, animal tests (predominantly the mouse Local Lymph Node Assay) are used to generate skin sensitisation hazard data for use in consumer safety risk assessments. An animal testing ban on chemicals to be used in cosmetics will come into effect in the European Union (EU) from March 2009. This animal testing ban is also linked to an EU marketing ban on products containing any ingredients that have been subsequently tested in animals, from March 2009 or March 2013, depending on the toxicological endpoint of concern. Consequently, the testing of cosmetic ingredients in animals for their potential to induce skin sensitisation will be subject to an EU marketing ban, from March 2013 onwards. Our conceptual framework and strategy to deliver a non-animal approach to consumer safety risk assessment can be summarised as an evaluation of new technologies (e.g. ‘omics’, informatics), leading to the development of new non-animal ( in silico and in vitro) predictive models for the generation and interpretation of new forms of hazard characterisation data, followed by the development of new risk assessment approaches to integrate these new forms of data and information in the context of human exposure. Following the principles of the conceptual framework, we have been investigating existing and developing new technologies, models and approaches, in order to explore the feasibility of delivering consumer safety risk assessment decisions in the absence of new animal data. We present here our progress in implementing this conceptual framework, with the skin sensitisation endpoint used as a case study.


2018 ◽  
Author(s):  
Michael H. Azarian

Abstract As counterfeiting techniques and processes grow in sophistication, the methods needed to detect these parts must keep pace. This has the unfortunate effect of raising the costs associated with managing this risk. In order to ensure that the resources devoted to counterfeit detection are commensurate with the potential effects and likelihood of counterfeit part usage in a particular application, a risk based methodology has been adopted for testing of electrical, electronic, and electromechanical (EEE) parts by the SAE AS6171 set of standards. This paper provides an overview of the risk assessment methodology employed within AS6171 to determine the testing that should be utilized to manage the risk associated with the use of a part. A scenario is constructed as a case study to illustrate how multiple solutions exist to address the risk for a particular situation, and the choice of any specific test plan can be made on the basis of practical considerations, such as cost, time, or the availability of particular test equipment.


2000 ◽  
Vol 14 (5) ◽  
pp. 1264-1270 ◽  
Author(s):  
Elisabeth Slooten ◽  
David Fletcher ◽  
Barbara L. Taylor
Keyword(s):  

2020 ◽  
Vol 34 (5) ◽  
pp. 627-640 ◽  
Author(s):  
Shi Xianwu ◽  
Qiu Jufei ◽  
Chen Bingrui ◽  
Zhang Xiaojie ◽  
Guo Haoshuang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document